首页> Translational lung cancer research> ALK-tyrosine kinase inhibitor intrinsic resistance due to de novoMET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report.

ALK-tyrosine kinase inhibitor intrinsic resistance due to de novoMET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report.

导出 LinkOut

翻译打印收藏纠错

第一作者： Edyta M,Urbanska

第一单位： Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

作者： Edyta M,Urbanska ^[1] ; Morten,Grauslund ^[2] ; Siv M S,Berger ^[3] ; Junia C,Costa ^[3] ; Peter R,Koffeldt ^[2] ; Jens B,Sørensen ^[4] ; Eric,Santoni-Rugiu ^[5]

作者单位： Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ^[1] Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ^[2] Department of Radiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ^[3] Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. ^[4] Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. ^[5]

关键词 ALK-rearranged non-small cell lung cancer (ALK-rearranged NSCLC)De novo MET-amplification case report intrinsic ALK-tyrosine kinase inhibitor resistance (intrinsic ALK-TKI resistance)tyrosine kinase inhibitor combination (TKI combination)

DOI 10.21037/tlcr-24-439

PMID 39430327

发布时间 2024-10-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Translational lung cancer research

2024年13卷9期

2453-2462页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Translational lung cancer research

2024年13卷9期

2453-2462页

检索历史清除

ALK-tyrosine kinase inhibitor intrinsic resistance due to <i>de novo</i><i>MET</i>-amplification in metastatic <i>ALK</i>-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report.

Translational lung cancer research

相似文献

同项目论文

Translational lung cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

ALK-tyrosine kinase inhibitor intrinsic resistance due to <i>de novo</i><i>MET</i>-amplification in metastatic <i>ALK</i>-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report.

Translational lung cancer research

相似文献

同项目论文

Translational lung cancer research

相关期刊

检索历史清除